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Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro
and demonstrate high clinical efficacy. To date they are routinely included into many
chemotherapeutic regimens. While the mechanisms of MT inhibitors’ interactions with
tubulin have been well-established, the relationship between their concentration and
effect on neoplastic cells is not completely understood. The common notion is that
tumor cells are most vulnerable during division and all MT inhibitors block them in
mitosis and induce mitotic checkpoint-associated cell death. At the same time multiple
evidence of more subtle effects of lower doses of MT inhibitors on cell physiology exist.
The extent of efficacy of the low-dose MT inhibitor treatment and the mechanisms of
resulting cell death currently present a critical issue in oncology. The prospect of MT
inhibitor dose reduction is promising as protocols at higher concentration have multiple
side effects. We assessed cell cycle changes and cell death induced by MT inhibitors
(paclitaxel, nocodazole, and vinorelbine) on human lymphoid B-cell lines in a broad
concentration range. All inhibitors had similar accumulation effects and demonstrated
“trigger” concentrations that induce cell accumulation in G2/M phase. Concentrations
slightly below the “trigger” promoted cell accumulation in sub-G1 phase. Multi-label
analysis of live cells showed that the sub-G1 population is heterogeneous and may
include cells that are still viable after 24 h of treatment. Effects observed were similar for
cells expressing Tat-protein. Thus cell cycle progression and cell death are differentially
affected by high and low MT inhibitor concentrations.
Keywords: cell cycle, cell death, microtubule inhibitors, paclitaxel, nocodazole, vinorelbine,
B-lymphocytes, RPMI8866
INTRODUCTION
The importance of microtubule (MT) dynamics for cell motility (Liao et al., 1995), migration
(Kaverina and Straube, 2011), and division (Jordan et al., 1993) has been well-established. The
multi-aspect effect of suppressed microtubule dynamics makes MT inhibitors an important part
of most anti-cancer chemotherapeutic regimens by inhibiting tumor growth (antimitotic effect)
and metastasis (antimigration effect) (Dumontet and Jordan, 2010).
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Microtubule inhibitors encompass several classes of
compounds with varying mechanisms of interactions with
tubulin (Perez, 2009) that disrupt MT dynamics by either
stabilizing or de-stabilizing them. MT inhibitors of the first
generation widely used in clinics (taxanes, vinca alkaloid
derivatives) have certain drawbacks, including neurotoxic effects
(Windebank, 1999), neutropenia (Donehower and Rowinsky,
1993) and loss of efficacy against advanced forms of some
cancers (Sève et al., 2008). Clinical limitations in treatment of
solid tumors and hematologic malignancies prompted further
research for analogs with improved clinical characteristics,
recently introducing vinflunine, epothilones, indibulin, and
many other (Bennouna et al., 2008; Cortes and Vidal, 2012).
Varying effects of high and low MT inhibitor concentrations
on different aspects of cell physiology have been described for
a number of cell models (Grigoriev et al., 1999; Yang et al.,
2010). The first meta-analysis focused on efficacy and toxicity
of low-dose versus conventional-dose chemotherapies has been
published recently (Xie et al., 2017) and provided data on
low-dose chemotherapy advantages.
Microtubule inhibitors are integrated into a variety of
chemotherapy schemes for B-cell malignancies, including the
curative regimens of non-Hodgkin lymphomas (Bates et al.,
2016). Their anti-cancer effects extend beyond their ability arrest
mitosis and include their potential to induce apoptosis at all
cell cycle phases (Bates and Eastman, 2017). The physiological
consequences of MT dynamics inhibition are still poorly
understood; the elucidation of its pleiotropic effects on cell death
and cell cycle will provide novel therapeutic strategies. In this
study we sought to determine the lowest efficient concentration
of several MT inhibitors and tested their dose-dependent effects
on cell death and mitotic arrest on B-cell lines RPMI8866
and its Tat-expressing modification RPMI8866-Tat-GFP. B-cell
lymphomas (Burkitt lymphoma, DLBCL, and B-CLL) are one
of the most common comorbid conditions for HIV-infected
patients (Gopal et al., 2013). B-cell oncogenesis in HIV patients
is related to Tat viral protein that enters B-lymphocytes, acts as
a transcription factor in oncogenic cascades (Vendrame et al.,
2014; Musinova et al., 2016) but also has cytoplasmic targets
including MTs (de Mareuil et al., 2005). To our knowledge,
no current research describes the effect of MT inhibitors on
Tat-expressing B-cells.
MATERIALS AND METHODS
Cell Lines and Microtubule Inhibitors
Human B-cell [RPMI8866 and Tat-GFP expressing RPMI8866
(RPMI8866-Tat-GFP)] and T-cell (Jurkat) lines were used in
the study. Cells were maintained in EX-CELL Medium (SAFC
Biosciences, United States) supplemented with L-glutamine and
10% FBS (Paneco, Russia). The effects of three MT inhibitors
on cell cycle and cell death were evaluated in the study:
paclitaxel (taxol; Sigma, United States), nocodazole (Biochem,
United States) and vinorelbine (Sigma, United States). MT
inhibitors were added to the medium 24 h prior to analysis at
final concentrations of 3; 10; 30; 100; 300; and 1000 nM.
Fluorescence Staining
Propidium iodide for DNA staining: The protocol for cell
cycle analysis in suspension cells was published previously
(Potashnikova et al., 2018).
Anti-caspase 3 immunostaining kit: PE-conjugated antibodies
against active caspase 3 (BD, United States) were used to assess
percentages of apoptotic cells. Cell fixation, permeabilization and
staining were performed using supplied buffers based on the
manufacturer’s instructions.
Multi-label cell cycle and apoptosis staining: live cell
suspensions of RPMI8866 and RPMI8866-Tat-GFP were
simultaneously stained with tetramethyl-rhodamine ethyl
ester (TMRE) for membrane potential, Hoechst33342
for DNA and annexin V-Alexa Fluor 647 (all Thermo
Fisher Scientific, United States) for phosphatidylserine
externalization. RPMI8866 cells were also stained with
CellEvent fluorescent caspase 3/7 substrate (Thermo Fisher
Scientific, United States): RPMI8866-Tat-GFP cells were
not stained with CellEvent to avoid fluorescence signal
conflict. The staining protocol was published previously
(Vorobjev and Barteneva, 2016).
Flow Cytometry
Cells were analyzed using a FACSAria SORP cell
sorter at Ex.407 nm/Em.425–475 nm for Hoechst33342,
Ex.488 nm/Em.515–535 nm for CellEvent, Ex.561 nm/Em.575–
590 nm for TMRE, PI and anti-caspase3-PE and
Ex.640 nm/Em.663–677 nm for annexin V-Alexa Fluor 647. Flow
cytometry data were acquired and analyzed using FACS Diva
v.6.1.3 software (BD, United States). Each measurement was
performed at least in triplicate.
Fluorescence Microscopy
Cell suspensions simultaneously stained with TMRE,
Hoechst33342, CellEvent and annexin V-Alexa Fluor
647 were analyzed using a Nikon Ti Eclipse microscope
under PlanApo 60×/1.4 objective. Images were recorded
by Hamamatsu ORCA FLASH2 digital camera, using the
following filter sets: Ex.450–490 nm/Em.510–540 nm; Ex.340–
380 nm/Em.435–485 nm; Ex.530–560 nm/Em.573–640 nm and
Ex.595–645 nm/Em.665–715 nm.
Statistical Analysis
Data from biological repeats were calculated as mean and
standard deviation and plotted in GraphPad Prism software
(United States). Unpaired t-test (95% confidence interval) was
used as significance test.
Electron Microscopy
Cells were fixed in 4% glutaraldehyde (Ted Pella, United States)
in 0.1 M Sørensen phosphate buffer for 2 h, post-fixed with 1%
osmium tetroxide (Sigma, United States) for 1 h, dehydrated in
ethanol and propylene oxide and embedded in Spi-pon 812 epoxy
resin (SPI Inc., United States). Ultrathin sections were cut using
an LKB III ultramicrotome (LKB), stained with uranyl acetate
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and lead citrate, and photographed using a JEM-1400 electron
microscope (Jeol, Japan)1.
RESULTS
The Mitostatic Response to Various MT
Inhibitor Concentrations Is Non-linear
We tested the mitostatic effect of three common stabilizing
(paclitaxel) and depolymerizing (nocodazole, vinorelbine) MT
inhibitors, on RPMI8866, RPMI8866-Tat-GFP (B-lymphocytes)
and Jurkat (T-lymphocytes) cell lines. Linear gates were set to
determine cell percentages at different cell cycle stages on DNA
content curves (Figures 1A–C).
Microtubule inhibitors uniformly prompted cell accumulation
in G2/M in a non-linear fashion: we found “trigger”
concentrations sufficient to accumulate cells in G2/M phase
that fell into 10–100 nM range for all inhibitors and cell
lines. Concentrations below the “trigger” retained cell cycle
1For Original Research articles, please note that the Material and Methods section
can be placed in any of the following ways: before Results, before Discussion or
after Discussion.
distribution close to normal. For example, for 3 nM paclitaxel we
observed 46% cells in G0/G1, 22% cells in S, and 18% in G2/M
for RPMI8866 cells compared to 53% cells in G0/G1, 20% cells
in S, and 18% in G2/M in control (Figure 1D). Concentrations
above the “trigger” increased the G2/M population peak with
a subsequent decrease of the G1 peak (Figures 1B,C and
Supplementary Figure S1). Similar response patterns were
achieved for every MT inhibitor; however, paclitaxel graphs were
chosen as most representative.
The Sub-G1 Population on DNA Content
Curves Likely Represents Apoptotic
Cells but Its Percentage Does Not
Correlate With Percentages of
Caspase-3 Positive Cells
The number of cells with sub-G1 DNA content increased
significantly in every MT inhibitor concentration compared to
untreated control (p < 0.05, unpaired t-test) (Figures 1A–C
and Supplementary Figure S1). Hypodiploid amounts of DNA
can be explained by nucleic acid degradation in late apoptosis.
Intriguingly, the largest sub-G1 populations did not correspond
FIGURE 1 | RPMI8866 B-lymphocytes untreated (control) and treated with paclitaxel (concentration range 3, 10, 30, 100, 300, and 1000 nM) for 24 h. (A–C) DNA
content curves in individual samples assessed by flow cytometry after propidium iodide staining and linear gates set to determine sub-G1, G0/G1, S, and G2/M cell
cycle populations. 50 000 events were analyzed per sample. (A) Normal cell cycle distribution in control cells; G2/M comprises 19% cells, sub-G1 comprises 5%
cells. (B) G2/M accumulation after 10 nM paclitaxel treatment; G2/M comprises 38% cells, sub-G1 comprises 25% cells. (C) G2/M accumulation after 1000 nM
paclitaxel treatment; G2/M comprises 63% cells, sub-G1 comprises 15% cells. (D) Data from biological repeats on sub-G1, G0/G1, S, and G2/M population
distributions were presented as mean percentages with SD on a histogram. Each measurement was performed at least in triplicate. (E) Miscorrelation of sub-G1
population numbers and caspase 3-positive cell numbers after paclitaxel treatment. The largest sub-G1 peak is observed at 10 nM paclitaxel while the largest
caspase 3-positive population is observed at 300 nM paclitaxel.
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to the highest MT inhibitor concentrations. Sub-G1 cell
percentages did not significantly differ at “trigger,” sub-“trigger”
and high MT inhibitor concentrations. The only significant
difference was obtained for paclitaxel: the highest percentage
of cells in sub-G1 (21%) was present in 10 nM paclitaxel; that
was significantly increased compared to 3, 300, and 1000 nM
paclitaxel and insignificantly different from 30 to 100 nM
paclitaxel (p < 0.05, unpaired t-test). To assess apoptosis levels,
cells were immunostained for active caspase 3. Lack of correlation
between sub-G1 and caspase 3-positive cell percentages was
observed (Figure 1E) as the number of caspase 3-positive cells
at 10 nM paclitaxel (13%) was similar to the numbers of
caspase 3-positive cells in the range of 3–100 nM paclitaxel.
To further investigate the apparent contradiction between the
results obtained by DNA content analysis and anti-caspase 3
staining a novel protocol for live cell analysis was developed and
tested on B-lymphocytes.
Live Cell Staining With Hoechst33342
Provides Similar Results to PI Staining
and Allows a Simultaneous
Multi-Parameter Apoptosis Assessment
Live cell suspensions of RPMI8866 and RPMI8866-Tat-GFP
were simultaneously stained with TMRE, Hoechst33342,
CellEvent fluorescent caspase 3/7 substrate and annexin
V-Alexa Fluor 647. Combined DNA content and apoptotic
marker cell labeling was visualized using flow cytometry
and fluorescence microscopy. Hoechst33342-based DNA
content analysis provided a dose response pattern similar to
PI staining with G2/M peak shift at “trigger” concentrations
(Supplementary Figure S2). Dying cells exhibit the typical
pattern of apoptotic events (Vorobjev and Barteneva, 2015):
the gradual TMRE fluorescence decrease corresponding to
mitochondrial membrane potential (MMP) loss, CellEvent
fluorescence corresponding to caspase 3 activation and annexin
V surface staining corresponding to phosphatidylserine
externalization (Figures 2D–I). This result was confirmed by
electron microscopy (Figures 2J–N): multiple apoptotic cells
were detected in the paclitaxel-treated specimen. Early stages
were characterized by chromatin marginalization; at later stages,
cell volume decreased markedly, accompanied by cytoplasm
condensation. Dead cells had destroyed plasma membranes and
cytoplasmic organelles, but inside them the residuals of nuclei
were still distinguishable.
Sub-G1 cell accumulation was observed at various rates
upon MT inhibitor treatment and was most prominent
in 10 nM paclitaxel (26%) (Figures 2A–C). The sub-G1
population was heterogeneous and contained cell debris
with apoptotic markers and low MMP and cells with no
apoptotic markers, hypodiploid DNA content and a two-fold
decreased MMP compared to live cells with normal ploidy.
Median TMRE fluorescence intensity was 976 a.u. for cell
debris, 22380 a.u. for hypodiploid cells and 48265 a.u.
for normal live cells (Figures 2F–G). Differences were
statistically significant (p < 0.05). Fluorescence microscopy
revealed live cells, apoptotic cells, cell debris and a fraction
of small-sized live cells, often with micronuclei and dim
mitochondria, in all MT inhibitor-treated specimens
(Supplementary Figure S3).
DISCUSSION
It was shown that MT inhibitor concentrations sufficient for
cell motility suppression can be lower than those needed for
mitotic arrest (Kapoor and Panda, 2012; Molina et al., 2013).
One of the thrilling questions is whether cytotoxic effects
can be exerted at low concentrations of MT inhibitors. To
answer this, we opted for a multi-parameter simultaneous
cell cycle and cell death assessment. The proposed approach
was derived from the two protocols described previously
(Vorobjev and Barteneva, 2016; Potashnikova et al., 2018). It
provides an easy and robust way to separately estimate the
cytotoxic and mitostatic effects of microtubule inhibitors. The
staining is suitable for high-throughput flow cytometry and
imaging flow cytometry, as well as for microscopic evaluation
of apoptosis kinetics in heterogeneous cell populations after
chemotherapeutic treatment.
Using such an approach we described the non-linear dose
response to an array of MT inhibitors, which seems to be
universal. The “trigger” concentrations fall between 10–30 nM
for paclitaxel, 30–100 nM for nocodazole and 10–30 nM for
vinorelbine. Increasing dosages do not significantly alter G2/M
accumulation. Despite the controversial data on B-cell responses
to various types of MT inhibitors (Beswick et al., 2006; Frezzato
et al., 2014) in our experiments the pattern of response to
all compounds was similar for all cell lines. Our data on cell
cycle accumulation and cell death percentages after MT inhibitor
treatment correspond to the published data on adherent cells
(Di Cesare et al., 2017).
Cells accumulated in G2/M phase die via apoptosis, exhibiting
mitochondrial membrane potential (MMP) decrease, caspase
activation and phosphatidylserine externalization. A sub-G1
population on DNA content curves includes late apoptotic
cells and cell debris. However, at low paclitaxel concentrations
this population also includes particularly large numbers
of cells with MMP decreased only two-fold compared to
normal cells and no markers of apoptosis. This explains the
miscorrelation between sub-G1 and caspase 3-positive cell
percentages observed in a range of paclitaxel concentrations.
Such addition biases the interpretation of sub-G1 population
as homogeneous and invariably apoptotic. Sub-G1 cells were
described in other cell models as potentially non-viable products
of aberrant mitosis (Demidenko et al., 2008) resulting from
MT inhibition. Using fluorescence microscopy we visualized
cells with smaller nuclei, often with micronuclei, and dim
TMRE staining that fit the description of such cells. While
their viability has to be further investigated, they present
a distinctly different pattern of response to MT inhibitors
compared to standard G2/M-accumulating cells that has to
be accounted for.
Interestingly, MT inhibitors had the same effect on
Tat-expressing B-lymphocytes (Supplementary Figures S1, S2).
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FIGURE 2 | RPMI8866 B-lymphocytes untreated (control) and treated with paclitaxel (10 and 1000 nM) for 24 h. (A–C) DNA content curves in individual samples
assessed by flow cytometry after Hoechst33342 staining and linear gates set to determine sub-G1, G0/G1, S, and G2/M cell cycle populations [colored
subpopulations correspond to live cells (green), apoptotic cells (brown), hypodiploid cells (purple) and cell debris (blue) as gated on dot plots (D–F)]. 50 000 events
were analyzed per sample. (A) Normal cell cycle distribution in control cells; G2/M comprises 18% cells, sub-G1 comprises 6% cells. (B) G2/M accumulation after
10 nM paclitaxel treatment; G2/M comprises 30% cells, sub-G1 comprises 26% cells. (C) G2/M accumulation after 1000 nM paclitaxel treatment; G2/M comprises
49% cells, sub-G1 comprises 19% cells. (D,F,H) Dot plots representing simultaneous staining of RPMI8866 B-lymphocytes with Hoechst33342, TMRE, annexin
V-Alexa Fluor 647, and CellEvent. Region gates are set to determine live cells (green), apoptotic cells (brown), hypodiploid cells (purple) and cell debris (blue) based
on Hoechst33342 vs. annexin V staining. (D) Normal apoptosis rate in control cells. Region gates are set to live cells (green) – 89.4%, apoptotic cells (brown) – 3.2%,
hypodiploid cells (purple) – 0.6% and cell debris (blue) – 6.8% based on Hoechst33342 vs. annexin V staining. The colors of the gated populations remain the same
in the TMRE vs. Hoechst33342 and CellEvent vs. annexin V graphs. (F) G2/M and sub-G1 accumulation after 10 nM paclitaxel treatment. Region gates are set to
live cells (green) – 69.0%, apoptotic cells (brown) – 4.9%, hypodiploid cells (purple) – 13.5% and cell debris (blue) – 12.6% based on Hoechst33342 vs. annexin V
staining. The colors of the gated populations remain the same in the TMRE vs. Hoechst33342 and CellEvent vs. annexin V graphs. (H) G2/M accumulation after
1000 nM paclitaxel treatment. Region gates are set to live cells (green) – 67.0%, apoptotic cells (brown) – 13.3%, hypodiploid cells (purple) – 1.6% and cell debris
(blue) – 18.1% based on Hoechst33342 vs. annexin V staining. The colors of the gated populations remain the same in the TMRE vs. Hoechst33342 and CellEvent
vs. annexin V graphs. (E,G,I) Fluorescence images of cells untreated (control) and treated with paclitaxel (10 and 1000 nM) for 24 h. Simultaneous staining of
RPMI8866 B-lymphocytes with Hoechst33342 (blue), TMRE (red), annexin V-Alexa 647 (yellow), and CellEvent (green). Scale bar – 10 µm. (E) Control cells; top two
images correspond to live cells with bright nuclear Hoechst33342 and mitochondrial TMRE fluorescence, bottom two images correspond to an apoptotic cell with
CellEvent staining in the nucleus and surface annexin V and cell debris with a dim nucleus and surface annexin V. (G) 10 nM paclitaxel treatment; top two images
correspond to live cells with bright nuclear Hoechst33342 and mitochondrial TMRE fluorescence, third image corresponds to an apoptotic cell with CellEvent staining
in the nucleus and surface annexin V, bottom image corresponds to aneuploid (hypodiploid) cell with dim mitochondrial TMRE fluorescence and micronuclei. White
arrowheads indicate micronuclei. (I) 1000 nM paclitaxel treatment; top two images correspond to live cells with bright nuclear Hoechst33342 and mitochondrial
TMRE fluorescence, bottom two images correspond to apoptotic cells with CellEvent staining in the nucleus and surface annexin V with/without micronuclei. White
arrowheads indicate micronuclei. (J–N) Electron microscopy of cells at various stages of apoptosis after 10 nM paclitaxel treatment. Scale bar – 2 µm. (J) Normal
cell with typical RPMI8866 lymphocyte morphology. (K) Chromatin marginalization. (L) Decrease of cell volume and condensation of cytoplasm (cell shrinkage). (M)
Early stage of cell destruction (secondary necrosis). (N) Cellular debris inside which the residual chromatin and cytoplasmic organelles can be distinguished.
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Despite some evidence of Tat protein interactions with
microtubules (de Mareuil et al., 2005) RPMI8866-Tat-GFP cells
do not differ from normal RPMI8866 lymphocytes in their
MT inhibitor responses. The relevance of our findings for
HIV-associated non-Hodgkin’s lymphoma model is important
for treating such patients.
Thus cell cycle arrest and cell death may be differentially
affected by high and low doses of MT inhibitors which has a big
therapeutic potential in oncology.
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FIGURE S1 | Lymphocytes treated with MT inhibitors (concentration range 3, 10,
30, 100, 300, and 1000 nM) for 24 h and stained for DNA content with propidium
iodide. Data from biological repeats on sub-G1, G0/G1, S, and G2/M population
distributions presented as mean percentages with SD on a histogram. Graphs in
columns represent RPMI8866 B-lymphocytes, RPMI8866-Tat-GFP
B-lymphocytes and Jurkat T-lymphocytes, respectively. Graphs in rows represent
paclitaxel, nocodazole and vinorelbine, respectively. Jurkat cells were previously
known to respond to MT inhibitors and were therefore used as control.
FIGURE S2 | Lymphocytes treated with MT inhibitors (concentration range 3, 10,
30, 100, 300, and 1000 nM) for 24 h and stained for DNA content with
Hoechst33342. Data from biological repeats on sub-G1, G0/G1, S, and G2/M
population distributions presented as mean percentages with SD on a histogram.
Graphs in columns represent RPMI8866 B-lymphocytes and RPMI8866-Tat-GFP
B-lymphocytes, respectively. Graphs in rows represent paclitaxel, nocodazole and
vinorelbine, respectively.
FIGURE S3 | Fluorescence image galleries of RPMI8866 B-lymphocytes treated
with a low dose of MT inhibitor 10 nM paclitaxel for 24 h. Simultaneous staining
with Hoechst33342 (blue), TMRE (red), annexin V-Alexa 647 (yellow), and
CellEvent (green). Scale bar – 10 µm. (A) Live cells with normal morphology have
bright round nuclei, bright mitochondrial TMRE fluorescence and bear no
apoptotic markers. (B) Apoptotic cells have TMRE-negative mitochondria,
CellEvent caspase substrate staining co-localized with nuclear staining and
surface-bound annexin V indicating phosphatidylserine externalization. (C) Cell
debris and late apoptotic cells have smaller size, irregular shape, TMRE-negative
mitochondria, deformed nuclei, often with CellEvent staining, and surface-bound
annexin V indicating phosphatidylserine externalization. (D) small-sized cells with
small nuclei, micronuclei, few TMRE-dim mitochondria, and no apoptotic markers.
White arrowheads indicate micronuclei.
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